OYAGEN Competitors and Similar CompaniesClear all
OYAGEN's competitors and similar companies include Ionis Pharmaceuticals, Omega Therapeutics, Intellia Therapeutics and Lexicon Pharmaceuticals.
 Ionis Pharmaceuticals Ionis Pharmaceuticals (formerly known as Isis Pharmaceuticals) is a company that discovers and develops RNA-targeted therapeutics. |  Intellia Therapeutics Intellia Therapeutics is a genome editing company that caters to the biotechnology industry. |  Lexicon Pharmaceuticals Lexicon Pharmaceuticals develops therapeutic products for diseases relating to immunology, metabolism, cardiology and ophthalmology. | |||
Founding Date | Founding Date 2003 | Founding Date 1989 | Founding Date 2017 | Founding Date 2014 | Founding Date 1995 |
Type | Type Private | Type Public | Type Public | Type Public | Type Public |
Tags | |||||
Locations | Locations Rochester, US HQ | Locations Cambridge, US HQ | Locations Cambridge, US HQ | Locations The Woodlands, US HQ Jersey, JE Atlanta, US Bernards, US Birmingham, US Boston, US Charlotte, US see more | |
Employees | Employees 5 | Employees 1,40231% increase | Employees 60 | Employees 40323% decrease | Employees 20216% increase |
Valuation ($) | Valuation ($) N/A | Valuation ($) 6.3 b | Valuation ($) 68.4 m | Valuation ($) 1.7 b | Valuation ($) 737.4 m |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) $943.7m (FY, 2025) | Revenue (est.) $3.1m (FY, 2023) | Revenue (est.) $67.7m (FY, 2025) | Revenue (est.) $49.8m (FY, 2025) |
Cost of goods | Cost of goods N/A | Cost of goods $15.9m (FY, 2025) | Cost of goods N/A | Cost of goods N/A | Cost of goods $274k (FY, 2025) |
Gross profit | Gross profit N/A | Gross profit $927.8m (FY, 2025) | Gross profit N/A | Gross profit N/A | Gross profit $49.5m (FY, 2025) |
Net income | Net income N/A | Net income ($381.4m) (FY, 2025) | Net income ($97.4m) (FY, 2023) | Net income ($412.7m) (FY, 2025) | Net income ($50.3m) (FY, 2025) |
Operating ⚠ | |||||
Phase I Trials Products | Phase I Trials Products N/A | Phase I Trials Products 1 (FY, 2023) | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products 1 (FY, 2016) |
Phase III Trials Products | Phase III Trials Products N/A | Phase III Trials Products 17 (FY, 2024) | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products 2 (FY, 2016) |
Funding | |||||
Total funding raised | Total funding raised $ 5.9m | Total funding raised N/A | Total funding raised $ 211m | Total funding raised N/A | Total funding raised $ 244.7m |
For sources of this data, please see the company profile
View Company Profiles
Ionis Pharmaceuticals
HQ
Carlsbad, US
Employees
1,402↑ 31% increase
Ionis Pharmaceuticals (formerly known as Isis Pharmaceuticals) is a company that discovers and develops RNA-targeted therapeutics.
View company
Omega Therapeutics
HQ
Cambridge, US
Employees
60
Omega Therapeutics is an epigenomic medicine company.
View companyIntellia Therapeutics
HQ
Cambridge, US
Employees
403↓ 23% decrease
Intellia Therapeutics is a genome editing company that caters to the biotechnology industry.
View companyLexicon Pharmaceuticals
HQ
The Woodlands, US
Employees
202↑ 16% increase
Lexicon Pharmaceuticals develops therapeutic products for diseases relating to immunology, metabolism, cardiology and ophthalmology.
View company